BioCentury
ARTICLE | Distillery Therapeutics

Neurology

January 23, 2019 12:08 AM UTC

In vitro and rat studies identified a mAb against the ADCYAP1-derived peptides PACAP-38 and PACAP-27 that could help treat migraine. In vitro screening of B cell cultures of PACAP-38-immunized rabbits for mAbs that inhibit both PACAP-38 and PACAP-27, followed by humanization of the top hit, yielded ALD1910, which bound PACAP-38 and PACAP-27 with Kd values of 22 and 59 pM, respectively. In a rat model of migraine, the mAb decreased facial temperature and lacrimation, both markers of migraine pain, compared with vehicle, and had a serum half-life of 188 hours. Next steps by Alder BioPharmaceuticals Inc. could include testing ALD1910 in other models of migraine...